XML 15 R4.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Net sales $ 572,619 $ 575,911 $ 1,126,598 $ 1,127,430
Cost of goods sold 264,850 274,244 507,067 523,560
Gross profit 307,769 301,667 619,531 603,870
Selling, general and administrative expense 201,257 210,425 408,838 419,555
Research and Development Expense 50,122 47,450 97,697 96,877
Segment profit (loss) 56,390 43,792 112,996 87,438
Interest expense 5,841 5,977 11,827 11,759
Foreign exchange (gains) losses, net 1,233 (15) 2,513 1,239
Unrealized Gain on Securities (716,389) (286,398) (1,775,619) (1,102,332)
Nonoperating Income (Expense) 3,896 15,858 22,592 27,003
Income before income taxes 769,601 340,086 1,896,867 1,203,775
(Provision) benefit for income taxes (170,791) (72,043) (432,862) (278,958)
Net income attributable to Bio-Rad $ 598,810 $ 268,043 $ 1,464,005 $ 924,817
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 20.08 $ 8.99 $ 49.12 $ 31.03
Weighted average common shares - basic 29,814 29,814 29,807 29,801
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 19.86 $ 8.87 $ 48.60 $ 30.63
Weighted average common shares - diluted 30,154 30,219 30,125 30,197